Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2013Journal of Clinical OncologyOpen Access

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRuben A. MesaUniversity of InsubriaJGJason GotlibOntario Institute for Cancer ResearchVGVikas GuptaSher-e-Kashmir University of Agricultural Sciences and Technology of Jammu

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mesa et al. (2013) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554c2https://doi.org/10.1200/jco.2012.44.4489
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement2011 · 62 citations
  2. 2A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,111 citations
  3. 3The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients2011 · 344 citations
  4. 4A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders2005 · 3,497 citations
  5. 5Myelofibrosis with Myeloid Metaplasia2000 · 747 citations